These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 25433809)
1. MicroRNA-mediated regulation of KRAS in cancer. Kim M; Slack FJ J Hematol Oncol; 2014 Nov; 7():84. PubMed ID: 25433809 [TBL] [Abstract][Full Text] [Related]
2. Targeted knock-in of the polymorphism rs61764370 does not affect KRAS expression but reduces let-7 levels. Crowley EH; Arena S; Lamba S; Di Nicolantonio F; Bardelli A Hum Mutat; 2014 Feb; 35(2):208-14. PubMed ID: 24282149 [TBL] [Abstract][Full Text] [Related]
3. Human cell line model for cancer-associated KRAS noncoding SNP. Lauring J Hum Mutat; 2014 Feb; 35(2):v. PubMed ID: 24415639 [No Abstract] [Full Text] [Related]
4. MicroRNA profiling predicts survival in anti-EGFR treated chemorefractory metastatic colorectal cancer patients with wild-type KRAS and BRAF. Mosakhani N; Lahti L; Borze I; Karjalainen-Lindsberg ML; Sundström J; Ristamäki R; Osterlund P; Knuutila S; Sarhadi VK Cancer Genet; 2012 Nov; 205(11):545-51. PubMed ID: 23098991 [TBL] [Abstract][Full Text] [Related]
5. MicroRNA profiling differentiates colorectal cancer according to KRAS status. Mosakhani N; Sarhadi VK; Borze I; Karjalainen-Lindsberg ML; Sundström J; Ristamäki R; Osterlund P; Knuutila S Genes Chromosomes Cancer; 2012 Jan; 51(1):1-9. PubMed ID: 21922590 [TBL] [Abstract][Full Text] [Related]
6. Gene of the month: KRAS. Chetty R; Govender D J Clin Pathol; 2013 Jul; 66(7):548-50. PubMed ID: 23626007 [TBL] [Abstract][Full Text] [Related]
7. miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer. Yu S; Lu Z; Liu C; Meng Y; Ma Y; Zhao W; Liu J; Yu J; Chen J Cancer Res; 2010 Jul; 70(14):6015-25. PubMed ID: 20610624 [TBL] [Abstract][Full Text] [Related]
8. Extensive sequence variation in the 3' untranslated region of the KRAS gene in lung and ovarian cancer cases. Kim M; Chen X; Chin LJ; Paranjape T; Speed WC; Kidd KK; Zhao H; Weidhaas JB; Slack FJ Cell Cycle; 2014; 13(6):1030-40. PubMed ID: 24552817 [TBL] [Abstract][Full Text] [Related]
9. A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk. Chin LJ; Ratner E; Leng S; Zhai R; Nallur S; Babar I; Muller RU; Straka E; Su L; Burki EA; Crowell RE; Patel R; Kulkarni T; Homer R; Zelterman D; Kidd KK; Zhu Y; Christiani DC; Belinsky SA; Slack FJ; Weidhaas JB Cancer Res; 2008 Oct; 68(20):8535-40. PubMed ID: 18922928 [TBL] [Abstract][Full Text] [Related]
10. Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer. Seth R; Crook S; Ibrahem S; Fadhil W; Jackson D; Ilyas M Gut; 2009 Sep; 58(9):1234-41. PubMed ID: 19474002 [TBL] [Abstract][Full Text] [Related]
11. [A Kras-specific function in cancer initiation]. Quinlan MP; Settleman J Ai Zheng; 2008 Jul; 27(7):673-4. PubMed ID: 18606056 [No Abstract] [Full Text] [Related]
12. KRAS 3'-UTR variants and stratification of breast-cancer risk. Kumar MS; Swanton C Lancet Oncol; 2011 Apr; 12(4):318-9. PubMed ID: 21435949 [No Abstract] [Full Text] [Related]
13. Aberrant microRNA expression likely controls RAS oncogene activation during malignant transformation of human prostate epithelial and stem cells by arsenic. Ngalame NN; Tokar EJ; Person RJ; Xu Y; Waalkes MP Toxicol Sci; 2014 Apr; 138(2):268-77. PubMed ID: 24431212 [TBL] [Abstract][Full Text] [Related]
14. A let-7 microRNA polymorphism in the KRAS 3'-UTR is prognostic in oropharyngeal cancer. De Ruyck K; Duprez F; Ferdinande L; Mbah C; Rios-Velazquez E; Hoebers F; Praet M; Deron P; Bonte K; Speel EJ; Libbrecht L; De Neve W; Lambin P; Thierens H Cancer Epidemiol; 2014 Oct; 38(5):591-8. PubMed ID: 25127693 [TBL] [Abstract][Full Text] [Related]
15. EVI1 oncogene promotes KRAS pathway through suppression of microRNA-96 in pancreatic carcinogenesis. Tanaka M; Suzuki HI; Shibahara J; Kunita A; Isagawa T; Yoshimi A; Kurokawa M; Miyazono K; Aburatani H; Ishikawa S; Fukayama M Oncogene; 2014 May; 33(19):2454-63. PubMed ID: 23752186 [TBL] [Abstract][Full Text] [Related]
16. KRAS alleles: the LCS6 3'UTR variant and KRAS coding sequence mutations in the NCI-60 panel. Kundu ST; Nallur S; Paranjape T; Boeke M; Weidhaas JB; Slack FJ Cell Cycle; 2012 Jan; 11(2):361-6. PubMed ID: 22189714 [TBL] [Abstract][Full Text] [Related]
17. The KRAS-variant and miRNA expression in RTOG endometrial cancer clinical trials 9708 and 9905. Lee LJ; Ratner E; Uduman M; Winter K; Boeke M; Greven KM; King S; Burke TW; Underhill K; Kim H; Boulware RJ; Yu H; Parkash V; Lu L; Gaffney D; Dicker AP; Weidhaas J PLoS One; 2014; 9(4):e94167. PubMed ID: 24732316 [TBL] [Abstract][Full Text] [Related]
18. Oncogenic KRAS regulates miR-200c and miR-221/222 in a 3D-specific manner in colorectal cancer cells. Tsunoda T; Takashima Y; Yoshida Y; Doi K; Tanaka Y; Fujimoto T; Machida T; Ota T; Koyanagi M; Kuroki M; Sasazuki T; Shirasawa S Anticancer Res; 2011 Jul; 31(7):2453-9. PubMed ID: 21873159 [TBL] [Abstract][Full Text] [Related]
19. KRAS up-regulates the expression of miR-181a, miR-200c and miR-210 in a three-dimensional-specific manner in DLD-1 colorectal cancer cells. Ota T; Doi K; Fujimoto T; Tanaka Y; Ogawa M; Matsuzaki H; Kuroki M; Miyamoto S; Shirasawa S; Tsunoda T Anticancer Res; 2012 Jun; 32(6):2271-5. PubMed ID: 22641662 [TBL] [Abstract][Full Text] [Related]